Elisabeth Gardiner, Ph.D.
Vice President of Translational Medicine
Elisabeth Gardiner is a biopharmaceutical professional with 17 years of experience conducting large- and small-molecule drug discovery from the whiteboard to clinic in a range of company settings. Contributing to multiple therapeutic candidates during her career, she most recently served as VP of Discovery Biology at Kinnate Biopharma where she facilitated hit to lead and compound optimization work for multiple preclinical programs.
Before Kinnate, she served as CSO of Meditope Biosciences, driving a novel antibody functionalization strategy for antibody-based therapeutics. Prior to Meditope, she was Director of Physiology Discovery at aTyr Pharma, managing the in vivo pharmacology and in vitro assay groups for large molecule drug discovery in the tRNA synthetase space. She was an Associate Director of high-throughput screening at the Genomics Institute of the Novartis Research Foundation contributing to the discovery of multiple therapeutic candidates, and held a variety of positions at Kalypsys, Inc., leading multiple projects in various therapeutic indications from screening to in vivo PoC.
Passionately devoted to developing effective therapies for patients she has been actively consulting for the past ten years, serving in scientific and strategic capacities for numerous pharmaceutical and technology companies. She continues to serve pro bono as a patient advocate in the rare disease and viral infection space. Elisabeth did her post-doc at The Scripps Research Institute, where she studied inflammation and oncology using high-content imaging. She is an author of numerous high-impact publications, and a co-inventor on multiple patents in the large and small molecule space. Elisabeth received her MS and BS from Texas A&M University and her PhD from the University of Wisconsin-Madison.